Happy Friday everyone!
The leaves are beginning to change, and so are ongoing activities at the FDA.
This week, we’re highlighting four FDA announcements we think you should hear about.
Check them out below!
FDA lists 205 molecular targets for pediatric cancer research
Scott Gottlieb addressed the lack of progress children’s cancer research has seen, and hopes that this new list of molecular targets may help speed things along.
FDA offers a proposal to help generic drug developers get simultaneous approvals in multiple markets
Scott Gottlieb has said that this change will make it easier for international drug companies to seek approvals in the US, increasing competition. This could mean new treatments get here faster.
The FDA Has Granted Orphan Status to a Potential Narcolepsy Drug
The narcolepsy community has been waiting for more and better treatment options, and the orphan drug designation is a big win that will speed one treatment along.
U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation for Pancreatic Cancer
Pancreatic cancer has a large unmet treatment need, but this designation will offer incentives encouraging development.
Share your stories, thoughts, and hopes with the Patient Worthy community!
